A confluence of factors, including a higher proportion of patients covered by public payers, has caused Gilead's powerhouse hepatitis C franchise to slow down and now begin showing signs of decline.
read full article ›A wave of data to support use of novel anticoagulants in real-world settings was presented at the European Society of Cardiology Congress, but the question is whether this will alter the course of the market still dominated by warfarin and trailed by J&J/Bayer's Xarelto.
read full article ›Express Scripts' plan to reimburse at levels according to value of specific indications in inflammatory diseases will create more space for new entrants with proven value.
read full article ›How Anti-CGRP mABs may fare in the migraine prevention space
read full article ›‘Patients are ready and willing to have conversations’ about trade-offs, National Health Council’s Perfetto says.
read full article ›This past Christmas weekend, Ana Memedovich had her best two days in more than a decade. Her 23-year-old son Mikhail has spinal muscular atrophy, or SMA, a rare genetic disease that has slowly robbed him of the ability to walk and function independently.
read full article ›Current versions by ASCO, NCCN, and others may not be right for insurers, but they are eyeing new ways to crunch the numbers for cost and outcomes.
read full article ›The Institute for Clinical and Economic Review has invited feedback on its methodology for calculating a drug's recommended price range. Industry response has been critical, but pharma can no longer afford to merely oppose value frameworks. It needs to create strategies for a world in which such frameworks are a permanent and influential part of the pricing and reimbursement landscape.
read full article ›Sales of Novartis' Entresto have been painfully slow and missed their 2016 target of $200m – but the big pharma hopes the heart failure drug's sales momentum will take off next year and it remains confident the first-in-class therapy will eventually reach peak annual sales of around $5bn.
read full article ›Post-FOURIER: what Amgen needs to do to improve Repatha reimbursement.
read full article ›